Agenus secures $22 million mortgage and announces strategic operational realignment

Lexington, mass.--(business wire)--agenus inc. (“agenus” or the “company”) (nasdaq: agen), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its berkeley-based biologics cmc facility ("901 heinz") and its 66-acre biomanufacturing-zoned property in vacaville, california. facilitated by l&l capital, the transaction yields $20 million in net proceeds after closing costs and interest reserve, bolstering the company's cash p.
AGEN Ratings Summary
AGEN Quant Ranking